COVID-19 vaccine development.In a statement on its website, the company said it expects to be able to manufacture 300 million vaccine doses annually, and that it aims to complete construction of a second production facility by the end of 2020 to increase annual COVID-19 vaccine production capacity to 600 million doses.Sinovac said the investor is Sino Biopharmaceutical Ltd.Click here to read the Mint ePaperMint is now on Telegram.